These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 25936328

  • 21. Lipoprotein apheresis results in plaque stabilization and prevention of cardiovascular events: comments on the prospective Pro(a)LiFe study.
    Klingel R, Heibges A, Fassbender C.
    Clin Res Cardiol Suppl; 2015 Apr; 10(Suppl 1):46-50. PubMed ID: 25644612
    [Abstract] [Full Text] [Related]

  • 22. Lipoprotein(a)--An independent causal risk factor for cardiovascular disease and current therapeutic options.
    Kassner U, Schlabs T, Rosada A, Steinhagen-Thiessen E.
    Atheroscler Suppl; 2015 May; 18():263-7. PubMed ID: 25936335
    [Abstract] [Full Text] [Related]

  • 23. Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?
    Schettler VJJ, Ringel J, Jacob S, Julius U, Klingel R, Heigl F, Roeseler E, Grützmacher P, German Society of Nephrology (DGfN) and the Foundation of German Centers of Nephrology (DN).
    Atheroscler Suppl; 2017 Nov; 30():44-49. PubMed ID: 29096860
    [Abstract] [Full Text] [Related]

  • 24. How to optimize lipoprotein apheresis treatment--a second look.
    Schettler V, Neumann CL, Hagenah GC, Schulz EG, Wieland E.
    Atheroscler Suppl; 2013 Jan; 14(1):89-92. PubMed ID: 23357148
    [Abstract] [Full Text] [Related]

  • 25. Factors inducing cardiovascular events in patients treated by lipoprotein apheresis.
    Taseva K, Fischer S, Passauer J, Weiss N, Bornstein SR, Julius U.
    Atheroscler Suppl; 2013 Jan; 14(1):45-50. PubMed ID: 23357140
    [Abstract] [Full Text] [Related]

  • 26. Lipoprotein apheresis in patients with peripheral artery disease and hyperlipoproteinemia(a).
    Poller WC, Dreger H, Morgera S, Berger A, Flessenkämper I, Enke-Melzer K.
    Atheroscler Suppl; 2015 May; 18():187-93. PubMed ID: 25936325
    [Abstract] [Full Text] [Related]

  • 27. Lipoprotein apheresis in Austria - Reduction of cardiovascular events by regular lipoprotein apheresis treatment.
    Berent T, Derfler K, Berent R, Sinzinger H.
    Atheroscler Suppl; 2019 Dec; 40():8-11. PubMed ID: 31818453
    [Abstract] [Full Text] [Related]

  • 28. Current situation of lipoprotein apheresis in Saxony.
    Julius U, Taseva K, Fischer S, Passauer J, Bornstein SR.
    Atheroscler Suppl; 2013 Jan; 14(1):51-5. PubMed ID: 23357141
    [Abstract] [Full Text] [Related]

  • 29. Kinetics of Lipoprotein(a) in patients undergoing weekly lipoprotein apheresis for Lp(a) hyperlipoproteinemia.
    Tselmin S, Müller G, Schatz U, Julius U, Bornstein SR, Hohenstein B.
    Atheroscler Suppl; 2017 Nov; 30():209-216. PubMed ID: 29096840
    [Abstract] [Full Text] [Related]

  • 30. Hyperlipoproteinaemia(a) - apheresis and emerging therapies.
    Vogt A.
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):12-17. PubMed ID: 28185213
    [Abstract] [Full Text] [Related]

  • 31. [Therapeutic algorithm for lipoprotein apheresis and PCSK9 inhibition for severe hypercholesterolemia or isolated lipoprotein(a) hyperlipoproteinemia].
    Schettler VJ, Ringel J, Jacob S, Julius U, Klingel R, Heigl F, Roeseler E, Grützmacher P, Deutsche Gesellschaft für Nephrologie (DGfN), Verband Deutsche Nierenzentren (DN).
    Internist (Berl); 2016 May; 57(5):511-6. PubMed ID: 27118008
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Lipoprotein(a)-apheresis in the light of new drug developments.
    Vogt A.
    Atheroscler Suppl; 2017 Nov; 30():38-43. PubMed ID: 29096859
    [Abstract] [Full Text] [Related]

  • 34. Association of lipoprotein(a) level with short- and long-term outcomes after CABG: The role of lipoprotein apheresis.
    Ezhov MV, Afanasieva OI, Il'ina LN, Safarova MS, Adamova IY, Matchin YG, Konovalov GA, Akchurin RS, Pokrovsky SN.
    Atheroscler Suppl; 2017 Nov; 30():187-192. PubMed ID: 29096836
    [Abstract] [Full Text] [Related]

  • 35. Impact of the German Lipoprotein Apheresis Registry (DLAR) on therapeutic options to reduce increased Lp(a) levels.
    Schettler VJ, Neumann CL, Peter C, Zimmermann T, Julius U, Roeseler E, Heigl F, German Apheresis Working Group.
    Clin Res Cardiol Suppl; 2015 Apr; 10(Suppl 1):14-20. PubMed ID: 25652812
    [Abstract] [Full Text] [Related]

  • 36. Lipoprotein apheresis in patients with peripheral artery disease and lipoprotein(a)-hyperlipoproteinemia: 2-year follow-up of a prospective single center study.
    Poller WC, Berger A, Dreger H, Morgera S, Enke-Melzer K.
    Atheroscler Suppl; 2017 Nov; 30():174-179. PubMed ID: 29096834
    [Abstract] [Full Text] [Related]

  • 37. Lipoprotein apheresis reduces adipocyte fatty acid-binding protein serum levels.
    Lamounier-Zepter V, Look C, Ehrhart-Bornstein M, Bornstein SR, Fischer S, Julius U.
    Atheroscler Suppl; 2013 Jan; 14(1):129-34. PubMed ID: 23357154
    [Abstract] [Full Text] [Related]

  • 38. Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a).
    Grützmacher P, Öhm B, Szymczak S, Dorbath C, Brzoska M, Kleinert C.
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):22-26. PubMed ID: 28233269
    [Abstract] [Full Text] [Related]

  • 39. Lipoprotein(a)-hyperlipoproteinemia as cause of chronic spinal cord ischemia resulting in progressive myelopathy - successful treatment with lipoprotein apheresis.
    Heigl F, Hettich R, Mauch E, Klingel R, Fassbender C.
    Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):50-54. PubMed ID: 28160245
    [Abstract] [Full Text] [Related]

  • 40. Long-term therapeutic efficacy of lipoprotein apheresis on circulating oxidative stress parameters--A comparison of two different apheresis techniques.
    Kopprasch S, Bornstein SR, Bergmann S, Graessler J, Julius U.
    Atheroscler Suppl; 2015 May; 18():80-4. PubMed ID: 25936309
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.